Enhancement of antibody response and delayed-type hypersensitivity by thalidomide in mice.
Fundam Clin Pharmacol
; 2(6): 493-7, 1988.
Article
em En
| MEDLINE
| ID: mdl-3240916
ABSTRACT
Renewed interest in thalidomide stemmed from the suggestion by several authors that it might prove useful against immune-related diseases. Despite interesting preliminary findings, little is actually known regarding its immunoenhancing properties in vivo. Male and female Swiss mice, aged 6-8 wk, were given 0.5 or 25 mg/kg/day of thalidomide orally for 4 wk. Various immunological parameters were then assessed. When compared to controls, mice exposed to the higher dose presented with a significantly increased thymus weight index, whereas spleen weight index remained unchanged. Anti-sheep erythrocyte plaque-forming cells and hemagglutinin titers were increased by 44% and 29%, respectively. Contact hypersensitivity to picryl chloride was enhanced by 62%. Finally, colloidal carbon clearance was not altered. Interestingly, the lower dose (5 mg/kg/day) exerted no effect whatsoever.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Talidomida
/
Hipersensibilidade Tardia
Limite:
Animals
Idioma:
En
Ano de publicação:
1988
Tipo de documento:
Article